SCHWARZENBRUCK, 26 April 2016 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the release of the next evolution in patient safety, Dolphin Online Ready Patient QA and Monitoring. Designed to revolutionize patient QA, leading to more efficiency and better patient safety, Dolphin enhances workflows in pre- treatment QA, while being mindful of future online treatment monitoring.

To achieve added efficiency, Dolphin offers a “plug and play” design that enables significantly faster pre-treatment QA. Dolphin only requires two minutes to set up and wirelessly transmits the measured detector response to the Dolphin workstation. Additionally, the new automatic verification software QuickCheck™ saves valuable time by providing instant analysis of the Dolphin measurements and giving an “OK” message for the tests successfully passed.

This design ensures that Dolphin will enable future online treatment monitoring by measuring the actual delivery during patient treatment and by automatic QuickCheck verification immediately after each fraction seamlessly integrating into the therapist’s workflow.

“The Dolphin will offer the possibility for online verification of complex dose delivery techniques such as IMRT or VMAT with the patient already in treatment position. Used for multiple treatment fractions the system even offers inherently a new possibility for cumulative delivered dose tracking,” said Dr. Hansjoerg Wertz, Dept. of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany in the name of the whole “dolphin team” at UMM. “The novel online QA system contributes to reduce extra pre-treatment QA time to a minimum while at the same time increasing patient safety and preventing severe accidents due to the immediate detection of dose delivery errors. Based on our intensive initial experiences we are planning to implement Dolphin into our clinical routine workflow for our patient verification during treatment as soon as possible. This gives us the ultimate confidence in treating our patients safely.”

Dolphin offers not only a simple consistency check but is coupled with the advanced analysis of each measured dose, and in turn, offers a complete patient QA solution. The clinical relevance of the dose discrepancies is comprehensively determined with DVH and in 3D patient anatomy using sophisticated TPS-Class verification software. Following this verification process, the clinical team can determine whether re-planning or plan adaptation is needed or machine-specific parameters can be verified.

Dolphin is also designed for future applications, such as Machine QA and Adaptive-QA™ using CBCT and dose of the day. The versatility of Dolphin makes it the universal detector for integrating future real time measurements into IBA’s myQA global QA platform for several key dosimetry applications, from Patient QA to Machine QA and more.

“We are proud to release Dolphin and believe, along with our reference customers, that it’s a milestone solution that will change the way patient QA is done for many years to come,” said Ralf Schira, Vice President Marketing of IBA Dosimetry. “As a first release, we will offer our customers a highly efficient solution for pre-treatment QA.

However, we are continuing to collaborate with our industry partners to release Dolphin for future online use, specifically, Dolphin with advanced Compass TPS-class software will serve as the basis for future Adaptive QA.

With the introduction of Dolphin and the ability to have it connected to the myQA® global QA platform, as well as gaining full patient QA overview via myQA Cockpit, users will have all QA tools in one place and every patient fraction at their fingertips.”

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba- worldwide.com.